Research Article

Synchronous and Metachronous Breast Malignancies: A Cross-Sectional Retrospective Study and Review of the Literature

Table 1

Population characteristics: data is presented, where appropriate, as mean value (±standard deviation) and one way , median value (interquartile range) and Kruskall-Wallis , or prevalence and chi-square test.

UBC1st MBC2nd MBC1st SBC2nd SBC

Women age 58.71 (±15.47)56.54 (±13.68)64.38 (±13.41)64.94 (±14.72)65.25 (±14.15)<0.05
BMI 26.74 (±5.24)26.17 (±6.14)25.18 (±4.64)0.556
Time interval between 1st and 2nd MBC 72 (40–120) N/A
Follow-up 79 (70–85)97 (82–120)66 (23–82)79 (72–90)<0.05
Tobacco smoke2.46% (13/528)0% (0/39)0% (0/16)0.500
Familial history0.95% (5/528)0% (0/39)6.25% (1/16)0.094
Mode of diagnosis
 Unknown4.55% (24/528)2.56% (1/39)2.5% (1/40)0% (0/16)0% (0/16)0.709
 Objective examination46.78% (247/528)69.23% (27/39)30% (12/40)31.25% (5/16)12.5% (2/16)<0.05
 Mammography36.17% (191/528)20.51% (8/39)57.5% (23/40)43.75% (7/16)62.5% (10/16)<0.05
 Ultrasound12.5% (66/528)7.69% (3/39)10% (4/40)25% (4/16)25% (4/16)0.236
Radiotherapy56.44% (241/427)64.86% (24/37)46.67% (7/15)0.442
Chemotherapy45.88% (195/425)47.22% (17/36)57.14% (8/14)0.703
Hormonal therapy70.85% (299/422)80.56% (29/36)100% (14/14)<0.05
 Tamoxifen therapy44.13% (233/528)53.85% (21/39)62.5% (10/16)0.187